; (ii) novel therapeutics for special populations, including pediatric populations, immunosuppressed individuals, and pregnant women; (iii) the development or testing of medical diagnostics to detect tuberculosis; (iv) public health interventions to address the epidemiology, mechanisms, and pathogenesis of tuberculosis, such as directly observed therapy and non-pharmaceutical intervention; (v) methods to enhance detection and response to outbreaks of tuberculosis, including multidrug resistant tuberculosis; and (vi) other relevant research areas. ; (E) in subparagraph (C), as so redesignated— (i) by redesignating clause (vi), as so redesignated, as clause (vii); (ii) in clause (v), as so redesignated, by striking ; and and inserting ; ; and (iii) by inserting after clause (v), as so redesignated, the following: (vi) the intensification of efforts to prevent, detect, and treat latent tuberculosis; and ; (F) in subparagraph (D), as so redesignated, by inserting before the period the following: , including public awareness campaigns and development of educational, risk, and media communications. ; (G) in subparagraph (F), as so redesignated, by striking paragraphs (1) through (4) and inserting subparagraphs (A) through (D) ; and (H) by adding at the end the following: (2) Selection In carrying out the activities described in paragraph (1), the Secretary— (A) is encouraged to give priority to programmatically relevant research so that new tools can be utilized in public health practice; and (B) may seek input from the Biomedical Advanced Research and Development Authority in identifying novel candidates to utilize in the efforts under this subsection to prevent, diagnose, and control tuberculosis. ; (3) by redesignating subsections (c) through (h) as subsections (d) through (i), respectively